News und Analysen
![Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/
(Photo: Business Wire)
Ipsen (Euronext: IPN; ADR
![Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
![Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
![Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Illumina to Announce Fourth Quarter and Fiscal Year 2019 Financial Results on Wednesday, January 29, 2020
Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2019 following the close of market on Wednesday, January 29, 2020.
On the same day, at
![Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
![Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
![Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Illumina Announces New Sequencing System, Partnership with Roche and Software Suite to Accelerate Adoption of Genomics
Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology and partnership
![Illumina and Roche Partner to Broaden Patient Access to Genomic Testing](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
![Illumina and Roche Partner to Broaden Patient Access to Genomic Testing](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
![Illumina and Roche Partner to Broaden Patient Access to Genomic Testing](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina and Roche Partner to Broaden Patient Access to Genomic Testing
Illumina, Inc. (NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Roche, a global pioneer in pharmaceuticals and diagnostics, today announced a 15-year
![Lantheus Holdings Announces Senior Leadership Appointment](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Lantheus Holdings Announces Senior Leadership Appointment
Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative
![ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
![Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan
![Waters to Acquire Andrew Alliance](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Waters to Acquire Andrew Alliance
Waters Corporation (NYSE:WAT) announced today that it has entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including
![Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
![Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be
![Novus Therapeutics Provides Update on OP0201](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
![Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019. Novocure plans to discuss these
![Morphosys: Milliarden für Anti-Krebs-Blockbuster](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
![Morphosys: Milliarden für Anti-Krebs-Blockbuster](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
![NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NanoString Provides Preliminary Operational and Financial Results for Fourth Quarter and FY 2019
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today provided preliminary operational and financial results for the fourth quarter
![Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
![Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
![Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch
![Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Illumina reicht Patentverletzungsklage gegen BGI in Schweden und dem Vereinigten Königreich ein
Illumina, Inc. (NASDAQ: ILMN) gab heute bekannt, dass das Unternehmen zwei weitere Patentverletzungsklagen im Zusammenhang mit den Sequenzierprodukten von BGI, einschließlich des DNBSeq-400 (auch